BioSpace News Archive

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced strong topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib compared with placebo plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 4:40 p.m. ET.

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that Blue Cross Blue Shield of Louisiana has joined the growing list of payors reducing the patient eligibility requirements for transcranial magnetic stimulation treatment from four failed medication trials to two.

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI ) today announced today the receipt of formal notification from the Nasdaq Stock Market (“Nasdaq”) that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders’ equity.

Mainz Biomed N.V. announces that Guido Baechler, Chief Executive Officer, and Bill Caragol, Chief Financial Officer, will present at the 35th Annual Piper Sandler Healthcare Conference taking place on the 28-30 November, 2023 in New York, NY, USA.

Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, announced that it has enrolled one third of its STAR-LLD 1b clinical trial.

iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, and CancerIQ, the precision cancer prevention platform streamlining provider workflows and activating high-risk patients, announced a new partnership to create a best-in-class breast health care solution.

Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence -powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced the closing of its license agreements with the Icahn School of Medicine at Mount Sinai, in New York, NY, to develop and commercialize electrocardiographic AI algorithms and assets.

MIRA Pharmaceuticals, Inc., an innovative pre-clinical-stage pharmaceutical company, announced a partnership with MIRALOGX, LLC, an intellectual property holding company established by MIRA’s founder.